Antiviral therapy after non-surgical tumor ablation in patients with hepatocellular carcinoma associated with hepatitis C virus

Journal of Gastroenterology and Hepatology (Australia)

Volumn 20, Issue 10, 2005, Pages 1553-1559

  Hung, Chao Hung ^a   Lee, Chuan Mo ^a   Wang, Jing Houng ^a   Tung, Hung Da ^a   Chen, Chien Hung ^a   Lu, Sheng Nan ^a  

^a CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

Author keywords

Antiviral therapy; Hepatitis C virus; Hepatocellular carcinoma; Recurrence; Survival

Indexed keywords

ALANINE AMINOTRANSFERASE; ALPHA2B INTERFERON; INTERFERON; RECOMBINANT ALPHA2B INTERFERON; RIBAVIRIN; VIRUS RNA; ANTIVIRUS AGENT;

ADULT; AGED; ANEMIA; APPETITE DISORDER; ARTICLE; CANCER SURVIVAL; CHEMOEMBOLIZATION; CLINICAL ARTICLE; DISEASE ASSOCIATION; DISEASE SEVERITY; DIZZINESS; FEMALE; FEVER; HEADACHE; HEPATITIS C VIRUS; HUMAN; INSOMNIA; LIVER CELL CARCINOMA; LIVER NODULE; MALAISE; MALE; PRIORITY JOURNAL; RASH; TUMOR RECURRENCE; BLOOD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; GENETICS; HEPATITIS C; LIVER TUMOR; MIDDLE AGED; RECURRENT DISEASE; SURVIVAL; TREATMENT OUTCOME; VIROLOGY;

AGED; ALANINE TRANSAMINASE; ANTIVIRAL AGENTS; CARCINOMA, HEPATOCELLULAR; FEMALE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON ALFA-2B; LIVER NEOPLASMS; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; RECURRENCE; RIBAVIRIN; RNA, VIRAL; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 33644693596     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/j.1440-1746.2005.03925.x     Document Type: Article

References (28)

1. Hasan F, Jeffers LJ, De Medina M et al. Hepatitis C-associated hepatocellular carcinoma. Hepatology 1990 12 : 589 91.
2. Poynard T, Bedossa P, Oplon P. for the OBSTIRC, METAVIR, CLINIVIR, and DOSVIRC groups. Nature history of liver fibrous progression in patients with chronic hepatitis C. Lancet 1997 349 : 825 32.
3. Lee CM, Lu SN, Changchien CS et al. Age, gender, and local geographic variations of viral etiology of hepatocellular carcinoma in a hyperendemic area for hepatitis B virus infection. Cancer 1999 86 : 1143 50.
4. Camma C, Di Marco V, Lo Iacono O et al. Long-term course of interferon-treated chronic hepatitis C. J. Hepatol. 1998 28 : 531 7.
5. Colombo M. Hepatitis C virus and hepatocellular carcinoma. Semin. Liver Dis. 1999 19 : 263 9.
6. Nishiguchi S, Kuroki T, Nakatani S et al. Randomised trial of effects of interferon-alpha on incidence of hepatocellular carcinoma in chronic active hepatitis C with cirrhosis. Lancet 1995 346 : 1051 5.
7. Mazzella G, Accogli E, Sottili S et al. Alpha interferon treatment may prevent hepatocellular carcinoma in HCV-related liver cirrhosis. J. Hepatol. 1996 24 : 141 7.
8. Lau DT, Kleiner DE, Ghany MG, Park Y, Schmid P, Hoofnagle JH. 10-year follow-up after interferon-alpha therapy for chronic hepatitis C. Hepatology 1998 28 : 1121 7.
9. Hino K, Kitase A, Satoh Y et al. Interferon retreatment reduces or delays the incidence of hepatocellular carcinoma in patients with chronic hepatitis C. J. Viral Hepat. 2002 9 : 370 6.
10. Omata M, Yoshida H. Resolution of liver cirrhosis and prevention of hepatocellular carcinoma by interferon therapy against chronic hepatitis C. Scand. J. Gastroenterol. Suppl. 2003 237 : 47 51.
11. Ikeda K, Arase Y, Saitoh S et al. Interferon beta prevents recurrence of hepatocellular carcinoma after complete resection or ablation of the primary tumor: a prospective randomized study of hepatitis C virus-related liver cancer. Hepatology 2000 32 : 228 32.
12. Kubo S, Nishiguchi S, Hirohashi K, Tanaka H, Shuto T, Kinoshita H. Randomized clinical trial of long-term outcome after resection of hepatitis C virus-related hepatocellular carcinoma by postoperative interferon therapy. Br. J. Surg. 2002 89 : 418 22.
13. Shiina S, Teratani T, Obi S, Hamamura K, Koike Y, Omata M. Nonsurgical treatment of hepatocellular carcinoma: from percutaneous ethanol injection therapy and percutaneous microwave coagulation therapy to radiofrequency ablation. Oncology 2002 62 : 64 8.
14. Livraghi T. Radiofrequency ablation, PEIT, and TACE for hepatocellular carcinoma. J. Hepatobil. Pancreat. Surg. 2003 10 : 67 76.
15. Barnett CC Jr., Curley SA. Ablative techniques for hepatocellular carcinoma. Semin. Oncol. 2001 28 : 487 96.
16. Shiratori Y, Shiina S, Teratani T et al. Interferon therapy after tumor ablation improves prognosis in patients with hepatocellular carcinoma associated with hepatitis C virus. Ann. Intern. Med. 2003 138 : 299 306.
17. Lin SM, Lin CJ, Hsu CW et al. Prospective randomized controlled study of interferon-alpha in preventing hepatocellular carcinoma recurrence after medical ablation therapy for primary tumors. Cancer 2004 100 : 376 82.
18. McHutchison JG, Gordon SC, Schiff ER et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. N. Engl. J. Med. 1998 339 : 1485 92.
19. Davis GL Esteban-Mur R Rustgi V et al. Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. International Hepatitis Interventional Therapy Group. N. Engl. J. Med. 1998 339 : 1493 9.
20. Manns MP, McHutchison JG, Gordon SC et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001 358 : 958 65.
21. Desmet VJ, Gerber M, Hoofnagle JH, Manns M, Scheuer PJ. Classification of chronic hepatitis: diagnosis, grading and staging. Hepatology 1994 19 : 1513 20.
22. Peduzzi P, Concato J, Kemper E, Holford TR, Feinstein AR. A simulation study of the number of events per variable in logistic regression analysis. J. Clin. Epidemiol. 1996 49 : 1373 9.
23. Tarao K, Rino Y, Ohkawa S et al. Close association between high serum alanine aminotransferase levels and multicentric hepatocarcinogenesis in patients with hepatitis C virus-associated cirrhosis. Cancer 2002 94 : 1787 95.
24. Miyaguchi S, Watanabe T, Takahashi H et al. Interferon therapy for hepatocellular carcinoma patients with low HCV-RNA levels. Hepatogastroenterology 2002 49 : 724 9.
25. Colleoni M, Buzzoni R, Bajetta E et al. A phase II study of mitoxantrone combined with beta-interferon in unresectable hepatocellular carcinoma. Cancer 1993 72 : 3196 201.
26. Dunk AA, Ikeda T, Pignatelli M, Thomas HC. Human lymphoblastoid interferon. In vitro and in vivo studies in hepatocellular carcinoma. J. Hepatol. 1986 2 : 419 29.
27. Lai CL, Lau JY, Wu PC et al. Recombinant interferon-alpha in inoperable hepatocellular carcinoma: a randomized controlled trial. Hepatology 1993 17 : 389 94.
28. Suzuki K, Ohkoshi S, Yano M et al. Sustained biochemical remission after interferon treatment may closely be related to the end of treatment biochemical response and associated with a lower incidence of hepatocarcinogenesis. Liver Int. 2003 23 : 143 7.